Jianping Wang

Prof. Jianping Wang


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 February 2026 in Cancer Medicine
Verified
Journal Article
Open access
YPYi Pan
Yi Pan
LCLin Chen
Lin Chen
YHYuqing Hu
Yuqing Hu
JCJie Chang
Jie Chang
XXXifeng Xu
Xifeng Xu
WXWenxia Xu
Wenxia Xu
Objective: Irinotecan, a standard therapeutic agent for metastatic colorectal cancer (mCRC), often faces significant limitations due to drug resistance, with treatment failure observed in approximately 30%–50% of patients, leading to poor clinical outcomes. This study aims to systematically elucidate the molecular mechanisms underlying irinotecan resistance in colorectal cancer (CRC) by constructing patient‐derived organoid (PDO) models combined with single‐cell transcriptomics technology. Methods: PDO models were successfully established from irinotecan‐resistant and sensitive CRC patients. Single‐cell RNA sequencing (scRNA‐seq) was performed on the organoids, analyzing the transcriptomic heterogeneity of 12,360 high‐quality cells. Gene Set Variation Analysis (GSVA), transcriptional regulatory networks, and cell communication networks were employed to dissect the resistance mechanisms. Results: Drug sensitivity assays demonstrated that the IC 50 value of irinotecan in CRC5 was significantly higher than that in CRC11, which was entirely consistent with their respective clinical phenotypes. Single‐cell sequencing identified CRC5‐specific drug‐resistant cell clusters, Cluster 1 and Cluster 6. Cluster 1 (MARCKSL1+) was characterized by the activation of the Wnt signaling pathway and extracellular matrix (ECM) remodeling, which collectively contributed to the maintenance of stem cell‐like properties, while Cluster 6 (AKR1C3+) exhibited significant enrichment in lipid metabolism and the Notch signaling pathway. Conclusion: This study integrates PDO models with single‐cell transcriptomics technology to reveal key cell subpopulations and molecular mechanisms underlying irinotecan resistance. The core mechanisms driving resistance involve the activation of Wnt signaling and the synergistic effect of lipid metabolism‐Notch pathways. Cluster 1 and Cluster 6 are identified as potential therapeutic targets, providing a theoretical basis for developing combination therapies targeting cancer stem cells or the metabolic microenvironment.

21 May 2025 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Open access
SZShicheng Zhou
Shicheng Zhou
DJDan Jiang
Dan Jiang
YLYu Liu
Yu Liu
QWQin Wang
Qin Wang
MHManyi Hu
Manyi Hu
JWJianping Wang
Jianping Wang
Colon cancer (CC) remains a significant global health burden, and the search for novel prognostic biomarkers and therapeutic targets is crucial. This study comprehensively analyzed the role of SIX2 (Sine Oculis Homeobox Homolog 2) in CC. Utilizing data from TCGA, GTEx, and CCLE databases, differential expression of SIX2 was observed in multiple cancers, with significant upregulation in many tumors compared to normal tissues. In CC, SIX2's differential expression was notable. Cox regression analysis revealed its prognostic significance, with overexpression associated with poor survival outcomes. SIX2 was strongly associated with gene alterations and correlated with key signaling pathways like WNT and TGF-β. In the tumor microenvironment, SIX2 was related to immune cell infiltration and immune-related molecules. Notably, in CC, it was associated with immunosuppressive cells and checkpoint molecules. Additionally, ABT737 was found to sensitize tumor immunotherapy in the context of SIX2. Animal experiments demonstrated that ABT737 effectively restricted the growth of CC in mice, and its combination with antiPD-1 immunotherapy was more effective. It could reduce the infiltration of CD163+ tumor-associated macrophages but without significantly increasing the infiltration of CD8+ T cells. Our findings suggest that SIX2 is a potential key player in CC, offering insights into future research and the development of targeted therapies.

9 September 2026 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
SHShuyang Hu
Shuyang Hu
XZXia Zhang
Xia Zhang
CGChenyang Ge
Chenyang Ge
SZShicheng Zhou
Shicheng Zhou
JBJing Ba
Jing Ba
CCCheng Cai
Cheng Cai
Background: Neoadjuvant PD-1/PD-L1 combined with chemoradiotherapy (CRT) has shown encouraging complete response (CR) rates in proficient mismatch repair (pMMR) or microsatellite-stable (MSS) locally advanced rectal cancer (LARC), yet immunotherapy duration varies widely across trials and its interaction with radiotherapy fractionation remains unclear. Methods: PubMed, Embase, and Cochrane Library were searched through October 8, 2025 for prospective trials of PD-1/PD-L1 inhibitors plus CRT in pMMR/MSS LARC. Random-effects models pooled CR (cCR+pCR) rates, with subgroup analyses and study-level meta-regression conducted to explore sources of heterogeneity. A linear probit model and an interactive quadratic probit model were applied to assess associations between treatment duration and response (PROSPERO number CRD420251253156). Results: Eighteen trials (972 patients; 10 LCRT-based and 8 SCRT-based) were included. Pooled CR and pCR rates were 44% (95% CI 0.38–0.49) and 40% (95% CI 0.36–0.45). CR was higher with SCRT plus ICI than LCRT plus ICI (50% vs 39%; P = 0.03), and pCR similarly favored SCRT (47% vs 34%; P < 0.01). Meta-regression identified radiotherapy fractionation and immunotherapy duration as study-level factors associated with CR. In analyses restricted to randomized controlled trials (RCTs), longer immunotherapy duration was positively associated with response. Exploratory quadratic models using all eligible studies suggested an inverted U-shaped pattern for LCRT (modeled peak at approximately 4.4 months) and a U-shaped pattern for SCRT (modeled trough at approximately 2.5 months). Conclusion: Among the included RCTs, longer immunotherapy duration was associated with higher response rates. The nonlinear patterns observed in the combined dataset were exploratory, may reflect heterogeneity between studies, and require prospective validation before informing treatment duration. Systematic review registration: https://www.crd.york.ac.uk/PROSPERO/view/CRD420261348026 , identifier CRD420251253156.

Verified
Journal Article
Open access
PDF file
YPYi Pan
Yi Pan
XWXuewei Wu
Xuewei Wu
LCLin Chen
Lin Chen
CZChao Zhang
Chao Zhang
YHY H
Y H
JWJianping Wang
Jianping Wang
Chemotherapy resistance remains a major challenge in colorectal cancer (CRC) treatment, necessitating novel adjuvant strategies. This study employed an integrated analytical strategy combining network pharmacology, single-cell RNA sequencing (scRNA-seq) of patient-derived organoids (PDOs) and molecular dynamics simulations to identify bioactive compounds from Ganoderma lucidum and elucidate their chemo-sensitizing mechanisms. Network pharmacology identified five bioactive components of G. lucidum, corresponding to 267 potential targets. Integration with transcriptomic data, weighted gene co-expression network analysis (WGCNA), and known CRC genes refined these to 19 core targets. Cross-referencing with scRNA-seq data from irinotecan-treated PDOs pinpointed cyclin-dependent kinase 2 (CDK2) and Aurora kinase A (AURKA) as pivotal targets. Molecular dynamics simulations confirmed stable binding of the key component cerevisterol to both CDK2 and AURKA proteins, with binding free energies of −120.67 kJ/mol and −134.47 kJ/mol, respectively. In vitro cell viability assays across multiple CRC cell lines (HCT116, RKO, and HT-29) and PDOs demonstrated that cerevisterol significantly sensitized CRC cells to irinotecan (SN38). Notably, we observed that CDK2 was preferentially enriched in MSI-H tumors, whereas AURKA was enriched in MSS tumors, suggesting the potential of MSI status as a biomarker for patient stratification. Collectively, these findings identify cerevisterol as a dual-targeting natural product that modulates CDK2 and AURKA to overcome chemotherapy resistance, providing a quantitative analytical framework for discovering bioactive compounds and their molecular targets from medicinal fungi.